Intimal Hyperplasia Evaluated by Optical Coherence Tomography (OCT) in de Novo Coronary Lesions Treated by Drug-eluting Balloon and Bare-metal Stent
NCT ID: NCT01057563
Last Updated: 2010-01-27
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Clinical Phase
PHASE4
Total Enrollment
30 participants
Study Classification
INTERVENTIONAL
Study Start Date
2009-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Restenosis due to neointimal hyperplasia causes repeat target vessel revascularization in a relevant number of patients undergoing percutaneous coronary interventions (PCI). Drug-eluting stents (DES) are currently adopted to reduce the rate of restenosis; however, they may increase risk of stent thrombosis.
Experimental data and first clinical experiences showed that inhibition of neointimal hyperplasia may be obtained by local administration of anti-proliferative drugs (like paclitaxel) loaded on the surface of angioplasty balloons. Data on the efficacy of novel coronary drug-eluting balloons (DEBs) are lacking.
Aims of this open label prospective, randomized trial is to evaluate neointimal hyperplasia in patients undergoing bare-metal stent (BMS) implantation alone compared to those receiving additional DEB use and to assess if the technique of DEB use may affect the degree of neointimal hyperplasia.
Neointimal hyperplasia will be assessed by Optical coherence tomography (OCT).
Experimental data and first clinical experiences showed that inhibition of neointimal hyperplasia may be obtained by local administration of anti-proliferative drugs (like paclitaxel) loaded on the surface of angioplasty balloons. Data on the efficacy of novel coronary drug-eluting balloons (DEBs) are lacking.
Aims of this open label prospective, randomized trial is to evaluate neointimal hyperplasia in patients undergoing bare-metal stent (BMS) implantation alone compared to those receiving additional DEB use and to assess if the technique of DEB use may affect the degree of neointimal hyperplasia.
Neointimal hyperplasia will be assessed by Optical coherence tomography (OCT).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
DCB in de Novo Coronary Lesion
NCT03691675
Drug-coated Balloon
UNKNOWN
NA
Optical Coherence Tomography to Evaluate Paclitaxel-Eluting Balloons and Everolimus-Eluting Coronary Stents
NCT01056744
Stents
Neointimal Proliferation
COMPLETED
PHASE4
Drug Eluting Balloon Efficacy for Small Coronary Vessel Disease Treatment
NCT03899818
Cardiovascular Diseases
COMPLETED
NA
The Clinical Efficacy and Safety of Drug-coated Balloon
NCT05133921
Coronary Heart Disease
Angioplasty, Balloon
COMPLETED
Intracoronary Stenting and Restenosis - Randomized Trial of Drug-eluting Stent Implantation or Drug-coated Balloon Angioplasty According to Neointima Morphology in Drug-eluting Stent Restenosis 5
NCT05544864
Coronary Artery Disease
Restenoses, Coronary
RECRUITING
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Background. Restenosis due to neointimal hyperplasia causes repeat target vessel revascularization in a relevant number of patients undergoing percutaneous coronary interventions (PCI). Drug-eluting stents (DES) are currently adopted to reduce the rate of restenosis and repeat revascularizations in the majority of cases. However, a known drawback that limits the clinical application of DES technology is the possible increased risk of stent thrombosis, requiring the need of a prolonged dual antiplatelet therapy. Such phenomenon is strongly related to the profound inhibition of stent strut endothelization, that leads to the presence of uncovered stent struts, and to the persistence of polymer molecules which may induce inflammatory reactions in the vessel wall.
Experimental data and first clinical experiences showed that inhibition of neointimal hyperplasia may be obtained by local administration of anti-proliferative drugs (like paclitaxel) loaded on the surface of angioplasty balloons. Accordingly, drug-eluting balloons (DEBs) are a promising tool to prevent restenosis and avoid the undesiderable persistence of polymer molecules of DES in the vessel wall, thus potentially increasing the safety of PCI Data on the efficacy of novel coronary DEBs and on the best technique to use them are lacking.
Optical coherence tomography (OCT), has a resolution of 5-10 μm, 10 times higher than intravascular ultrasound, thus allowing fine characterization of stent strut coverage and apposition and detection of minimal degree of in-stent neointima hyperplasia.
Objective of the study:
* To evaluate the degree of neointimal hyperplasia in patients undergoing bare-metal stent (BMS) implantation alone compared to those receiving additional DEB use.
* To assess if the technique of DEB use (pre-dilation or post-dilation) may affect the degree of neointimal hyperplasia after BMS implantation.
Study Design. Open label prospective randomized trial comparing the degree of neointimal hyperplasia assessed by OCT in patients treated by BMS implantation alone, BMS implantation after DEB predilation or BMS followed by DEB postdilation.
Consecutive patients undergoing BMS implantation and agreeing to enter the study will be randomized 1:1:1 to
1. BMS implantation.
2. BMS implantation after lesion predilation with DEB
3. BMS implantation followed by post-dilation with DEB. Enrolled patients will undergo a 6-month follow up coronary angiography with OCT evaluation of the stented segment. OCT analysis will be performed by an expert OCT analyst (GF) blinded to the treatment assignment.
Study population. 30 subjects.
Procedure Description. In all eligible patients, PCI with BMS implantation will be performed according to the physician standard practice. All patients will be pre-treated with dual antiplatelet therapy.
General considerations on DEB usage. DEB is mainly intended to serve as drug delivery to the vessel wall and should therefore always cover the stenotic area as well as any extended pre-treated (injured) vessel area including the target lesion and any adjacent (prox and distal) portions when these were eventually previously covered by a stent or dilated by a balloon catheter, incidentally or by intention.
DEB length and positioning within the target lesion must be therefore carefully chosen to avoid geographic miss between the DEB and such extended pre-treated vessel area.
1. BMS group procedure:
* Lesion predilation with an undersized semi-compliant balloon (balloon to artery ratio: 0.5/1).
* BMS implantation (stent to artery ration: 1.1/1).
* Post-dilation of the stented segment with a non-compliant balloon at high pressure (16-18 atm)
2. PRE-DEB group procedure:
1. Pre-dilation
* Pre-dilatation of the target lesion with an undersized semi-compliant standard PTCA balloon (balloon to artery ratio: 0.5/1)
2. DEB dilation:
* DEB diameter and pressure: nominal DEB diameter must be chosen to guarantee full vessel wall contact at a pressure close or slightly higher of the DEB nominal pressure (balloon to artery ratio: 1/1)
* DEB length: nominal DEB length must exceed 10 mm (5mm per edge) the length of the stent which is planned to be deployed
* DEB inflation time: 45 seconds
3. BMS implantation
4. Post-dilation
* Post dilatation of the stented segment must be performed with a non-compliant PTCA balloon
* Balloon diameter: nominal PTCA balloon diameter must be chosen to reach a balloon to stent ratio of 1:1 at high pressure (16-18 atm)
* Balloon length and positioning: PTCA balloon length should be shorter than the length of the deployed stent . In case of post stent edge residual stenosis post-dilation balloon must fall within are outside the stent (5mm per edge) which was the previously dilated by the DEB
3. POST-DEB group procedure:
1. Pre-dilation
* Pre-dilatation of the target lesion must be performed with an undersized semi-compliant standard PTCA balloon (balloon to artery ratio: 0.5/1)
2. BMS implantation
* stent to artery ratio: 1.1/1
* stent length must allow full coverage of the target lesion with a single stent as well as be 10 mm shorter than the DEB which the operator is planning to use next
3. Post-dilation
* Post dilatation of the stented segment must be performed with a non-compliant PTCA balloon
* Balloon diameter: nominal PTCA balloon diameter must be chosen to reach a balloon to stent ratio of 1:1 at high pressure (16-18 atm)
4. DEB-dilation
* DEB length and positioning: DEB length must be 10 mm longer than the previously deployed stent (or than the extended pre-treated area in case of former post-dilation outside the stent edges) and centred within such pre-treated length (5mm per edge)
* DEB inflation time: 45 seconds
* Balloon to stent ratio: 1.1:1 at a pressure close or slightly higher of the DEB nominal pressure
The result of the procedure will be assessed by 3-dimensional QCA.
Post-procedural management. All patients will undergo cardiac damage markers (Creatin-kinase-MB and Troponin I) assessment before the procedure, 6 hours after PCI and 24 hours after PCI. Thereafter, further blood samples will be performed only if clinically indicated.
After PCI, patients will be given aspirin (75-100 mg/die) life-long and clopidogrel (75 mg/die) for 3 months (according to the on-label prescription for DEB-treated patients).
Follow-up. Clinical follow-up will take place at 1 month (±1 week), 6 months (±2 weeks) and 1 year (±30 days). At 6-month follow-up all patients will undergo a quantitative coronary angiography (3-dimensional QCA) and Optical Coherence Tomography (OCT) study.
OCT analysis. OCT will be performed with the Imaging system M2 (LightLab Imaging Inc., Westford, Massachusetts), capable of a pullback speed of 2 mm/sec and acquisition frame rate of 15.6/sec, using a non-occlusive technique, with continuous intracoronary iso-osmolar contrast injection.
The entire stent length will be assessed and cross sectional images will be analysed every 0.5 mm.
STRUT COVERAGE The struts will be classified as uncovered if a tissue layer on the endoluminal surface is not visible or covered in the presence of visibile tissue between the endoluminal surface and the lumen.
The tissue coverage thickness will be measured in each strut as the distance from the strut endoluminal surface to the lumen. In each cross section analysed, the following parameters will be calculated: the percentage of covered struts (the number of covered struts/ total number of struts), the percentage of uncovered struts (number of uncovered struts/ total number of struts), the tissue coverage thickness (μm), the tissue coverage area (stent area - lumen area) and its percentage (tissue coverage area/stent area X 100); the tissue volume coverage (tissue coverage area x stent length) and its percentage (tissue coverage volume/stent volume X 100). To assess the pattern of coverage, the ratio between the difference of maximum and the minimum tissue thickness/maximum tissue coverage will be calculated in each frame. A ratio close to 1 indicates an asymmetric tissue coverage, on the opposite a ratio close to 0 indicates a symmetric tissue coverage.
INCOMPLETE STENT APPOSITION A single stent strut will be defined with incomplete stent apposition (ISA) when the distance between its endoluminal surface and the vessel wall will be higher than the entire strut thickness. ISA will be considered present if at least one single strut will be incompletely apposed to the vessel wall. In each OCT frame analysed, the number of struts with ISA and the maximum distance from the endoluminal stent strut to the vessel wall will be measured. The percentage of struts with ISA (number of struts with ISA/total number of struts), according to the presence/absence of tissue coverage, will also be reported. A strut will be defined as protruding when the strut will protrude into the lumen relative to the intima between the adjacent strut sections and the distance between its endoluminal surface and the vessel wall will be less than the entire strut thickness and higher than half of strut thickness. The percentage of protruding struts (number of protruding struts/total number of strut X 100) will be reported, according to the presence/absence of tissue coverage.
Sample size calculation and statistical analysis. The primary endpoint is the neointimal area. Secondary endpoints will be the percentage of uncovered struts, the percentage of struts with ISA and the percentage of protruding struts.
This OCT study is a superiority study and it is expected that additional DEB use to BMS implantation will lead to a reduction of the primary endpoint compared to BMS implantation alone.
Few information is available on neointimal proliferation after BMS implantation: two small non randomized studies reported maximal and minimal neointimal thickness (mm) at 7.3 month follow up (first study) and mean neointimal thickness at 8 month follow up (latter study) being \> 4 folds higher in the BMS group compared to the rapamycin eluting stent group, although data on neointimal area are not available. A recent randomized study comparing 12 polymer coated rapamycin-eluting stents to 12 non polymer rapamycin eluting stents reported a neointimal area of 0.3 ± 0.2 mm2 in the polymer stent vs 1.2 ± 0.8 mm2in the non polymer stent, thus with a difference of 0.9 (95% CI 0.3-1.4). Based on these findings, we may hypothesize that additional DEB use will yield to a value of neointimal area close to that reported in the non polymer rapamycin eluting stent and that this would correspond to approximately 50% reduction of neointimal area in the BMS group. To detect such difference, 10 patients will be required in each group with a power of 0.9 at a two- sided type I error of 0.05. As we cannot anticipate whether the timing of additional DEB use: pre or post stenting, might have a different effect on the reduction of neointimal hyperplasia, 10 patients will be allocated in a randomized fashion to the predilatation DEB use group, 10 patients to the postdilatation DEB use group and 10 to the BMS group.
Experimental data and first clinical experiences showed that inhibition of neointimal hyperplasia may be obtained by local administration of anti-proliferative drugs (like paclitaxel) loaded on the surface of angioplasty balloons. Accordingly, drug-eluting balloons (DEBs) are a promising tool to prevent restenosis and avoid the undesiderable persistence of polymer molecules of DES in the vessel wall, thus potentially increasing the safety of PCI Data on the efficacy of novel coronary DEBs and on the best technique to use them are lacking.
Optical coherence tomography (OCT), has a resolution of 5-10 μm, 10 times higher than intravascular ultrasound, thus allowing fine characterization of stent strut coverage and apposition and detection of minimal degree of in-stent neointima hyperplasia.
Objective of the study:
* To evaluate the degree of neointimal hyperplasia in patients undergoing bare-metal stent (BMS) implantation alone compared to those receiving additional DEB use.
* To assess if the technique of DEB use (pre-dilation or post-dilation) may affect the degree of neointimal hyperplasia after BMS implantation.
Study Design. Open label prospective randomized trial comparing the degree of neointimal hyperplasia assessed by OCT in patients treated by BMS implantation alone, BMS implantation after DEB predilation or BMS followed by DEB postdilation.
Consecutive patients undergoing BMS implantation and agreeing to enter the study will be randomized 1:1:1 to
1. BMS implantation.
2. BMS implantation after lesion predilation with DEB
3. BMS implantation followed by post-dilation with DEB. Enrolled patients will undergo a 6-month follow up coronary angiography with OCT evaluation of the stented segment. OCT analysis will be performed by an expert OCT analyst (GF) blinded to the treatment assignment.
Study population. 30 subjects.
Procedure Description. In all eligible patients, PCI with BMS implantation will be performed according to the physician standard practice. All patients will be pre-treated with dual antiplatelet therapy.
General considerations on DEB usage. DEB is mainly intended to serve as drug delivery to the vessel wall and should therefore always cover the stenotic area as well as any extended pre-treated (injured) vessel area including the target lesion and any adjacent (prox and distal) portions when these were eventually previously covered by a stent or dilated by a balloon catheter, incidentally or by intention.
DEB length and positioning within the target lesion must be therefore carefully chosen to avoid geographic miss between the DEB and such extended pre-treated vessel area.
1. BMS group procedure:
* Lesion predilation with an undersized semi-compliant balloon (balloon to artery ratio: 0.5/1).
* BMS implantation (stent to artery ration: 1.1/1).
* Post-dilation of the stented segment with a non-compliant balloon at high pressure (16-18 atm)
2. PRE-DEB group procedure:
1. Pre-dilation
* Pre-dilatation of the target lesion with an undersized semi-compliant standard PTCA balloon (balloon to artery ratio: 0.5/1)
2. DEB dilation:
* DEB diameter and pressure: nominal DEB diameter must be chosen to guarantee full vessel wall contact at a pressure close or slightly higher of the DEB nominal pressure (balloon to artery ratio: 1/1)
* DEB length: nominal DEB length must exceed 10 mm (5mm per edge) the length of the stent which is planned to be deployed
* DEB inflation time: 45 seconds
3. BMS implantation
4. Post-dilation
* Post dilatation of the stented segment must be performed with a non-compliant PTCA balloon
* Balloon diameter: nominal PTCA balloon diameter must be chosen to reach a balloon to stent ratio of 1:1 at high pressure (16-18 atm)
* Balloon length and positioning: PTCA balloon length should be shorter than the length of the deployed stent . In case of post stent edge residual stenosis post-dilation balloon must fall within are outside the stent (5mm per edge) which was the previously dilated by the DEB
3. POST-DEB group procedure:
1. Pre-dilation
* Pre-dilatation of the target lesion must be performed with an undersized semi-compliant standard PTCA balloon (balloon to artery ratio: 0.5/1)
2. BMS implantation
* stent to artery ratio: 1.1/1
* stent length must allow full coverage of the target lesion with a single stent as well as be 10 mm shorter than the DEB which the operator is planning to use next
3. Post-dilation
* Post dilatation of the stented segment must be performed with a non-compliant PTCA balloon
* Balloon diameter: nominal PTCA balloon diameter must be chosen to reach a balloon to stent ratio of 1:1 at high pressure (16-18 atm)
4. DEB-dilation
* DEB length and positioning: DEB length must be 10 mm longer than the previously deployed stent (or than the extended pre-treated area in case of former post-dilation outside the stent edges) and centred within such pre-treated length (5mm per edge)
* DEB inflation time: 45 seconds
* Balloon to stent ratio: 1.1:1 at a pressure close or slightly higher of the DEB nominal pressure
The result of the procedure will be assessed by 3-dimensional QCA.
Post-procedural management. All patients will undergo cardiac damage markers (Creatin-kinase-MB and Troponin I) assessment before the procedure, 6 hours after PCI and 24 hours after PCI. Thereafter, further blood samples will be performed only if clinically indicated.
After PCI, patients will be given aspirin (75-100 mg/die) life-long and clopidogrel (75 mg/die) for 3 months (according to the on-label prescription for DEB-treated patients).
Follow-up. Clinical follow-up will take place at 1 month (±1 week), 6 months (±2 weeks) and 1 year (±30 days). At 6-month follow-up all patients will undergo a quantitative coronary angiography (3-dimensional QCA) and Optical Coherence Tomography (OCT) study.
OCT analysis. OCT will be performed with the Imaging system M2 (LightLab Imaging Inc., Westford, Massachusetts), capable of a pullback speed of 2 mm/sec and acquisition frame rate of 15.6/sec, using a non-occlusive technique, with continuous intracoronary iso-osmolar contrast injection.
The entire stent length will be assessed and cross sectional images will be analysed every 0.5 mm.
STRUT COVERAGE The struts will be classified as uncovered if a tissue layer on the endoluminal surface is not visible or covered in the presence of visibile tissue between the endoluminal surface and the lumen.
The tissue coverage thickness will be measured in each strut as the distance from the strut endoluminal surface to the lumen. In each cross section analysed, the following parameters will be calculated: the percentage of covered struts (the number of covered struts/ total number of struts), the percentage of uncovered struts (number of uncovered struts/ total number of struts), the tissue coverage thickness (μm), the tissue coverage area (stent area - lumen area) and its percentage (tissue coverage area/stent area X 100); the tissue volume coverage (tissue coverage area x stent length) and its percentage (tissue coverage volume/stent volume X 100). To assess the pattern of coverage, the ratio between the difference of maximum and the minimum tissue thickness/maximum tissue coverage will be calculated in each frame. A ratio close to 1 indicates an asymmetric tissue coverage, on the opposite a ratio close to 0 indicates a symmetric tissue coverage.
INCOMPLETE STENT APPOSITION A single stent strut will be defined with incomplete stent apposition (ISA) when the distance between its endoluminal surface and the vessel wall will be higher than the entire strut thickness. ISA will be considered present if at least one single strut will be incompletely apposed to the vessel wall. In each OCT frame analysed, the number of struts with ISA and the maximum distance from the endoluminal stent strut to the vessel wall will be measured. The percentage of struts with ISA (number of struts with ISA/total number of struts), according to the presence/absence of tissue coverage, will also be reported. A strut will be defined as protruding when the strut will protrude into the lumen relative to the intima between the adjacent strut sections and the distance between its endoluminal surface and the vessel wall will be less than the entire strut thickness and higher than half of strut thickness. The percentage of protruding struts (number of protruding struts/total number of strut X 100) will be reported, according to the presence/absence of tissue coverage.
Sample size calculation and statistical analysis. The primary endpoint is the neointimal area. Secondary endpoints will be the percentage of uncovered struts, the percentage of struts with ISA and the percentage of protruding struts.
This OCT study is a superiority study and it is expected that additional DEB use to BMS implantation will lead to a reduction of the primary endpoint compared to BMS implantation alone.
Few information is available on neointimal proliferation after BMS implantation: two small non randomized studies reported maximal and minimal neointimal thickness (mm) at 7.3 month follow up (first study) and mean neointimal thickness at 8 month follow up (latter study) being \> 4 folds higher in the BMS group compared to the rapamycin eluting stent group, although data on neointimal area are not available. A recent randomized study comparing 12 polymer coated rapamycin-eluting stents to 12 non polymer rapamycin eluting stents reported a neointimal area of 0.3 ± 0.2 mm2 in the polymer stent vs 1.2 ± 0.8 mm2in the non polymer stent, thus with a difference of 0.9 (95% CI 0.3-1.4). Based on these findings, we may hypothesize that additional DEB use will yield to a value of neointimal area close to that reported in the non polymer rapamycin eluting stent and that this would correspond to approximately 50% reduction of neointimal area in the BMS group. To detect such difference, 10 patients will be required in each group with a power of 0.9 at a two- sided type I error of 0.05. As we cannot anticipate whether the timing of additional DEB use: pre or post stenting, might have a different effect on the reduction of neointimal hyperplasia, 10 patients will be allocated in a randomized fashion to the predilatation DEB use group, 10 patients to the postdilatation DEB use group and 10 to the BMS group.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Coronary Artery Disease
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
BMS group
Patients undergoing PCI with BMS implantation
Group Type
ACTIVE_COMPARATOR
bare-metal stent (BMS)
Intervention Type
DEVICE
BMS implantation
PRE-DEB group
Patients undergoing PCI with BMS implantation after lesion predilation with DEB
Group Type
ACTIVE_COMPARATOR
drug (paclitaxel)-eluting balloon (DEB)
Intervention Type
DEVICE
BMS implantation after lesion predilation with DEB
POST-DEB group
Patients undergoing PCI with BMS implantation followed by postdilation with DEB
Group Type
ACTIVE_COMPARATOR
Drug (paclitaxel)-eluting balloon (DEB)
Intervention Type
DEVICE
BMS implantation followed by post-dilation with DEB
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
drug (paclitaxel)-eluting balloon (DEB)
BMS implantation after lesion predilation with DEB
Intervention Type
DEVICE
bare-metal stent (BMS)
BMS implantation
Intervention Type
DEVICE
Drug (paclitaxel)-eluting balloon (DEB)
BMS implantation followed by post-dilation with DEB
Intervention Type
DEVICE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Non-diabetic patients with a stable coronary artery disease, undergoing elective PCI with BMS
* de novo non-complex lesions (no bifurcation lesions, no chronic total occlusions, no severe calcifications, no moderate-to-severe tortuosities) located in straight coronary segments.
* lesion length ≥10 mm and \<25 mm.
* vessel size requiring a single stent with diameter between 3.0 and 3.5mm.
* de novo non-complex lesions (no bifurcation lesions, no chronic total occlusions, no severe calcifications, no moderate-to-severe tortuosities) located in straight coronary segments.
* lesion length ≥10 mm and \<25 mm.
* vessel size requiring a single stent with diameter between 3.0 and 3.5mm.
Exclusion Criteria
Clinical:
* age \<18 years or impossibility to give informed consent,
* diabetes mellitus
* female sex with child-bearing potential,
* life expectancy less than 6 months or any condition impeding clinical follow-up (no fixed address, etc),
* significant platelet count alteration (\<100,000 cells/mm3 or \> 700,000 cells/mm3),
* gastrointestinal bleeding requiring surgery or blood transfusions within 4 previous weeks,
* participation to another study with any investigational device or drug within which is still in the active phase.
* history of clotting pathology, known hypersensitivity to aspirin, heparin, cobalt- chromium, paclitaxel, contrast dye,
* renal failure with creatinine value \> 2.5 mg/dl,
* poor cardiac function as defined by left ventricular global ejection fraction ≤ 30%
* acute myocardial infarction within the past 48 hours.
* non ST-elevation acute coronary syndrome
Angiographic:
* left main coronary artery disease,
* lesions in coronary artery bypass grafts,
* no suitable anatomy for OCT scan
* bifurcation lesions, chronic total occlusions, severe calcifications, moderate-to-severe tortuosities
* presence of additional non target lesions requiring treatment, within and outside the target vessel, which are not successfully treated (non target lesions must be treated prior to the target lesion)
* age \<18 years or impossibility to give informed consent,
* diabetes mellitus
* female sex with child-bearing potential,
* life expectancy less than 6 months or any condition impeding clinical follow-up (no fixed address, etc),
* significant platelet count alteration (\<100,000 cells/mm3 or \> 700,000 cells/mm3),
* gastrointestinal bleeding requiring surgery or blood transfusions within 4 previous weeks,
* participation to another study with any investigational device or drug within which is still in the active phase.
* history of clotting pathology, known hypersensitivity to aspirin, heparin, cobalt- chromium, paclitaxel, contrast dye,
* renal failure with creatinine value \> 2.5 mg/dl,
* poor cardiac function as defined by left ventricular global ejection fraction ≤ 30%
* acute myocardial infarction within the past 48 hours.
* non ST-elevation acute coronary syndrome
Angiographic:
* left main coronary artery disease,
* lesions in coronary artery bypass grafts,
* no suitable anatomy for OCT scan
* bifurcation lesions, chronic total occlusions, severe calcifications, moderate-to-severe tortuosities
* presence of additional non target lesions requiring treatment, within and outside the target vessel, which are not successfully treated (non target lesions must be treated prior to the target lesion)
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Catholic University of the Sacred Heart
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Catholic University of Sacred Heart
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Francesco Burzotta, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Catholic University of Sacred Heart
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Institute of Cardiology, Catholic University of Sacred Heart
Rome, , Italy
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Italy
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Waugh J, Wagstaff AJ. The paclitaxel (TAXUS)-eluting stent: a review of its use in the management of de novo coronary artery lesions. Am J Cardiovasc Drugs. 2004;4(4):257-68. doi: 10.2165/00129784-200404040-00006.
Reference Type
BACKGROUND
Unverdorben M, Vallbracht C, Cremers B, Heuer H, Hengstenberg C, Maikowski C, Werner GS, Antoni D, Kleber FX, Bocksch W, Leschke M, Ackermann H, Boxberger M, Speck U, Degenhardt R, Scheller B. Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis. Circulation. 2009 Jun 16;119(23):2986-94. doi: 10.1161/CIRCULATIONAHA.108.839282. Epub 2009 Jun 1.
Reference Type
BACKGROUND
Scheller B, Hehrlein C, Bocksch W, Rutsch W, Haghi D, Dietz U, Bohm M, Speck U. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med. 2006 Nov 16;355(20):2113-24. doi: 10.1056/NEJMoa061254. Epub 2006 Nov 13.
Reference Type
BACKGROUND
Scheller B, Hehrlein C, Bocksch W, Rutsch W, Haghi D, Dietz U, Bohm M, Speck U. Two year follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. Clin Res Cardiol. 2008 Oct;97(10):773-81. doi: 10.1007/s00392-008-0682-5. Epub 2008 Jun 5.
Reference Type
BACKGROUND
Prati F, Cera M, Ramazzotti V, Imola F, Giudice R, Albertucci M. Safety and feasibility of a new non-occlusive technique for facilitated intracoronary optical coherence tomography (OCT) acquisition in various clinical and anatomical scenarios. EuroIntervention. 2007 Nov;3(3):365-70. doi: 10.4244/eijv3i3a66.
Reference Type
BACKGROUND
Chen BX, Ma FY, Luo W, Ruan JH, Xie WL, Zhao XZ, Sun SH, Guo XM, Wang F, Tian T, Chu XW. Neointimal coverage of bare-metal and sirolimus-eluting stents evaluated with optical coherence tomography. Heart. 2008 May;94(5):566-70. doi: 10.1136/hrt.2007.118679.
Reference Type
BACKGROUND
7. Tatsuya I, Mitsuyasu T, Yoshihiro T. Optical coherence tomography analysis of neointimal stent coverage in sirolimus eluting stents compared with bare metal stents. American College of Cardiology Scientific Sessions 2006. J Am Coll Cardiol 2006;47 Suppl:A2906-73
Reference Type
BACKGROUND
Moore P, Barlis P, Spiro J, Ghimire G, Roughton M, Di Mario C, Wallis W, Ilsley C, Mitchell A, Mason M, Kharbanda R, Vincent P, Sherwin S, Dalby M. A randomized optical coherence tomography study of coronary stent strut coverage and luminal protrusion with rapamycin-eluting stents. JACC Cardiovasc Interv. 2009 May;2(5):437-44. doi: 10.1016/j.jcin.2009.01.010.
Reference Type
BACKGROUND
Burzotta F, Brancati MF, Trani C, Pirozzolo G, De Maria G, Leone AM, Niccoli G, Porto I, Prati F, Crea F. Impact of drug-eluting balloon (pre- or post-) dilation on neointima formation in de novo lesions treated by bare-metal stent: the IN-PACT CORO trial. Heart Vessels. 2016 May;31(5):677-86. doi: 10.1007/s00380-015-0671-3. Epub 2015 Apr 12.
Reference Type
DERIVED
De Maria GL, Porto I, Burzotta F, Brancati MF, Trani C, Pirozzolo G, Leone AM, Niccoli G, Prati F, Crea F. Dual role of circulating endothelial progenitor cells in stent struts endothelialisation and neointimal regrowth: a substudy of the IN-PACT CORO trial. Cardiovasc Revasc Med. 2015 Jan-Feb;16(1):20-6. doi: 10.1016/j.carrev.2014.10.008. Epub 2014 Oct 31.
Reference Type
DERIVED
Burzotta F, Brancati MF, Trani C, Porto I, Tommasino A, De Maria G, Niccoli G, Leone AM, Coluccia V, Schiavoni G, Crea F. INtimal hyPerplasia evAluated by oCT in de novo COROnary lesions treated by drug-eluting balloon and bare-metal stent (IN-PACT CORO): study protocol for a randomized controlled trial. Trials. 2012 May 6;13:55. doi: 10.1186/1745-6215-13-55.
Reference Type
DERIVED
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A/582/CE/2009
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Drug-eluting Stents vs. Drug-coated Balloon for Preventing Recurrent In-stent Restenosis
NCT01967199
TERMINATED
PHASE4
Optical Coherence Tomography in Long Lesions
NCT01133925
UNKNOWN
PHASE4
Drug-Coated Balloon in Combination With New Generation Drug-Eluting Stent for de Novo Diffuse Disease Treatment
NCT03939468
UNKNOWN
Optical Coherence Tomography Following Paclitaxel Eluting Stent Implantation in Multivessel Coronary Artery Disease
NCT00704145
COMPLETED
PHASE4
Paclitaxel Releasing Balloon in Patients Presenting With In-Stent Restenosis
NCT00961181
COMPLETED
NA
Optical Coherence Tomography Comparison of Neointimal Coverage Between CRE8 DES and BMS
NCT01543373
COMPLETED
NA
Paclitaxel-coated Balloon for Treatment of De-novo Non-complex Coronary Artery Lesions
NCT04561739
ACTIVE_NOT_RECRUITING
NA
Balloon Elution and Late Loss Optimization (BELLO) Study
NCT01086579
UNKNOWN
NA
Optimization of Percutaenous Coronary Intervention With Liberal Use of Post-dilatation
NCT06558474
RECRUITING
Drug-coated Balloons and Drug-eluting Stents in Diabetic Patients
NCT05937230
ACTIVE_NOT_RECRUITING
Drug-coated Balloon Versus Drug-eluting Stent for de Novo Lesions in Large Coronary Arteries Guided by Optical Coherence Tomography
NCT04664283
UNKNOWN
NA
A Safety and Efficacy Study of Dissolve™ in Treatment of Coronary In-stent Restenosis
NCT03373695
COMPLETED
NA
Paclitaxel-Coated Balloon Versus Zotarolimus-Eluting Stent for Treatment of De Novo Coronary Artery Lesions
NCT05209412
ACTIVE_NOT_RECRUITING
NA
Drug Eluting Balloon Versus Drug Eluting Stent in PCI
NCT01760200
COMPLETED
DCB vs. DES in Bifurcation Coronary Lesions
NCT06551662
RECRUITING
NA
DEB vs Thin-DES in DES-ISR: Long Term Outcomes (DEB Dragon Registry)
NCT04415216
COMPLETED
Safety and Efficacy of Drug-Coated Balloon for De-novo Lesions in Patients With Acute Coronary Syndromes (DCB-ACS)
NCT04937803
COMPLETED
NA
Optical Coherence Tomography for Drug Eluting Stent Safety
NCT00693030
UNKNOWN
PHASE4
Drug Eluting Balloon for Prevention of Constrictive Remodeling
NCT01690572
TERMINATED
NA
Assess the Efficacy and Safety of RESTORE Paclitaxel Eluting Balloon Versus RESOLUTE Zotarolimus Eluting Stent for the Treatment of Small Coronary Vessel Disease
NCT02946307
COMPLETED
NA
Comparison of Drug Eluting Balloon and Drug Eluting Stent
NCT01539603
COMPLETED
PHASE2
DRUG RELEASING BALL vs. PHARMACOACTIVE STENT IN LARGE VESSELS: MORPHOLOGICAL ANALYSIS AND FUNCTION VASOMOTOR (DEBORA STUDY) IN LARGE VESSELS: MORPHOLOGICAL ANALYSIS AND FUNCTION VASOMOTOR (DEBORA STUDY)
NCT06448637
RECRUITING
NA
Paclitaxel-coated or Uncoated AngioSculpt Scoring Balloon Catheter
NCT01495533
COMPLETED
PHASE3